No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
MRK Merck & Co
- 128.120
- +0.360+0.28%
Close Jul 15 16:00 ET
- 128.120
- 0.0000.00%
Pre 05:02 ET
324.50BMarket Cap142.36P/E (TTM)
128.340High127.200Low6.92MVolume128.000Open127.760Pre Close884.94MTurnover0.27%Turnover Ratio915.14P/E (Static)2.53BShares134.63052wk High8.04P/B323.70BFloat Cap97.22452wk Low3.00Dividend TTM2.53BShs Float134.630Historical High2.34%Div YieldTTM0.89%Amplitude18.121Historical Low127.906Avg Price1Lot Size
Pre-Market
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Wells Fargo Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $140
Wells Fargo analyst Mohit Bansal maintains $Merck & Co(MRK.US)$ with a hold rating, and maintains the target price at $140.According to TipRanks data, the analyst has a success rate of 63.9% and a
Jeito Capital Consolidates Its Support in CatalYm With a Renewed Participation in a $150 Million Financing
Jeito Capital consolidates its support in CatalYm with a renewed participation in a $150 million financing
Bernie Sanders: 'Getting Sick In America Should Not Mean Going Bankrupt, Losing Your Home, Car, Or Life Savings'
Sen. Bernie Sanders (I-Vt.) recently expressed his concerns about the high cost of medical care in the United States, highlighting the financial burden it places on patients.
Merck & Co., Inc. (NYSE:MRK) Is Favoured by Institutional Owners Who Hold 78% of the Company
Key Insights Given the large stake in the stock by institutions, Merck's stock price might be vulnerable to their trading decisions The top 25 shareholders own 45% of the company Using data from
Trump's Betting Election Odds Surge After Assassination Attempt, How Would The Market React?
On Saturday, Donald Trump was shot at a campaign rally in Pennsylvania, which could be a key moment that completely disrupts the US election landscape this year. Following the incident, data from Polymarket shows that Trump's chances of winning the election have skyrocketed to 71%.
Express News | Merck & Co Inc : Guggenheim Cuts Target Price to $142 From $146
Comments
On Saturday, Donald Trump was shot at a campaign rally in Pennsylvania, which could be a key moment that completely disrupts the US election landscape this year. Following the incident, data from Polymarket shows that Trump's chances of winning the election have skyrocketed to 71%.
After shooting, Bitcoin price briefly surpassed $63,000. $Trump Media & Technology(DJT.US$ surged over 70% in Mond...
After shooting, Bitcoin price briefly surpassed $63,000. $Trump Media & Technology(DJT.US$ surged over 70% in Mond...
95
7
President Joe Biden, 81, has stated he remains committed to his re-election campaign despite slipping polling numbers and concerns about his recent public performances.
Reports suggest Biden acknowledged the importance of his upcoming appearances, though the White House denies this claim. His stumbling debate performance and questions about his mental acuity have caused panic within the Democratic Party, leading to speculation about a...
Reports suggest Biden acknowledged the importance of his upcoming appearances, though the White House denies this claim. His stumbling debate performance and questions about his mental acuity have caused panic within the Democratic Party, leading to speculation about a...
88
18
$Merck & Co(MRK.US$I think it’s just a temp pullback, it just broke the double-bottom line as well as the recent resistence simetanously. The pullback volume is also lower. Expecting new ATH.
5
$Merck & Co(MRK.US$ on the prowl for acquisitions up to $15 billion.
$Merck & Co(MRK.US$ already has an active partnership with $Janux Therapeutics(JANX.US$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US$ in which $Merck & Co(MRK.US$ already has a seat at the table.
$Merck & Co(MRK.US$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
$Merck & Co(MRK.US$ already has an active partnership with $Janux Therapeutics(JANX.US$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF(XBI.US$ in which $Merck & Co(MRK.US$ already has a seat at the table.
$Merck & Co(MRK.US$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
+1
9
🔥 3 PDUFA decisions this week! 👇
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
📌 This week’s PDUFAs:
$Merck & Co(MRK.US$ : 🤔
⇨ Patritumab deruxtecan
‣ Non-small cell lung carcinoma
‣ PDUFA date: 6/26/24 (BLA)
$Verona Pharma(VRNA.US$ : 🤔
⇨ Ensifentrine (Nebulized)
‣ Chronic obstructive pulmonary disease
‣ PDUFA date: 6/26/24 (NDA)
$Genmab(GMAB.US$ : 🤔
⇨ EPKINLY® (Epcoritamab)
‣ Follicular lymphoma
‣ PDUFA date: 6/28/24 (sBLA)
🗓️ Last week’s PDUFAs:
$Merck & Co(MRK.US$ : Approved 6/17 🎉
⇨ CAPVAXIVE (V116)
‣ Pneumo...
9
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
White_Shadow :
Mark Paluzzi White_Shadow: fake news he got cut falling down!
david Roberts7 : you go mr. president
70729743 :
sick4cash : He was almost assassinated By a conservative, what are you talking about?His own people
View more comments...